ClinicalTrials.gg
Active, not recruitingNCT06707883Updated Dec 12, 2025

A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

A Phase 2 interventional study of TQC2731 injection and TQC2731 Placebo in Chronic Obstructive Pulmonary Disease, sponsored by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.. Active, not recruiting at 60 sites in China. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-12.

Sponsored by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
258
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited — 2 open to participants now, 6 under way, 2 of them phase 3. Pulmonary Disease, Chronic Obstructive · Sino Biopharmaceutical Limited.

Enrollment
3rd of 17
258 · median 113
Started
2024
with 5 others
Phase 2
8 of 17
none open now
Registered
10th of 17
by date

Among the 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited, this one is the 3rd largest by enrollment, is one of 6 that started in 2024, is one of 8 in phase 2, and was the 10th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of TQC2731 injection in patients with moderate to severe chronic obstructive pulmonary disease.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able and willing to provide written and comply with the study protocol;
  • Participant must be ≥40 to ≤80 years of age at the time of signing informed consent.
  • Participants with a physician diagnosis of (COPD) and a history of COPD ≥12 months with medical records or related records at the time of screening;
  • Post-bronchodilator /Forced vital capacity (FVC)\<0.70 and post-bronchodilator FEV1 % predicted ≥20% and \< 80% during screening.
  • Modified Medical Research Council (mMRC) Dyspnea Scale grade≥2 during screening.
  • Background triple therapy (ICS+long-acting beta-agonists (LABA)+LAMA) for at least 3 months with a stable dose for at least 1 month prior to randomization; Double therapy allowed if ICS is .
  • With a history of acute exacerbation of ≥2 moderate or ≥1 severe within the previous 12 months prior to screening. Multiple acute exacerbation events with an interval of less than 14 days are counted as one.

Exclusion criteria

Exclusion Criteria:

  • with asthma;
  • Subjects with active pulmonary diseases other than COPD assessed by the investigator.
  • Moderate to severe Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) occurred within 4 weeks prior to screening or during screening;
  • History of lung transplantation;
  • Previous use of TQC2731.
  • Diagnosis of alpha-1 anti-trypsin deficiency;
  • History of lung volume reduction surgery or pneumonectomy within 6 months prior to randomization, or planned lung volume reduction surgery during the study period;
  • Positive surface antigen, or virus antibody, or syphilis antibody.
  • Diagnosis of immunodeficiency, including but not limited to infection;
  • Infection requiring systemic therapy within 2 weeks prior to randomization.
  • Starting rehabilitation within 4 weeks prior to randomization, or planned rehabilitation during the study period;
  • Treatment with oxygen of more than 12 hours per day.
  • Heart failure (NYHA) class III or IV during the screening period.
  • History of within 5 years prior to screening, excluding cervical carcinoma in situ, ductal carcinoma in situ, etc.
  • Pregnancy or breastfeeding.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
258 participants (actual)

Study arms

  • Experimental
    TQC2731 injection

    TQC2731 injection, 28days as a treatment cycle.

    Drug: TQC2731 injection

  • Placebo comparator
    TQC2731 Placebo

    TQC2731 Placebo, 28days as a treatment cycle.

    Drug: TQC2731 Placebo

Interventions

  • TQC2731 injection is a monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP)

  • DrugTQC2731 Placebo

    TQC2731 Placebo without drug substance.

06

What researchers measure

Primary outcomes

  1. Annual rate of acute COPD exacerbation

    Annualized rate of moderate or severe COPD exacerbations over the 24-week treatment period compared to placebo

    Time frame: Baseline to week 24

Secondary outcomes

  1. Change in pre-bronchodilator forced expiratory volume (FEV1)

    Change in pre-bronchodilator FEV1 from baseline to week 24 compared to placebo.

    Time frame: Baseline to week 24

  2. Annual rate of acute COPD exacerbation

    Annualized rate of moderate COPD exacerbations over the 52-week treatment period compared to placebo.

    Time frame: Baseline to week 52

  3. Improvement in St. George's Respiratory Questionnaire (SGRQ)

    Proportion of patients with SGRQ improvement ≥4 points at Week 52

    Time frame: Baseline to week 52

  4. Change in SGRQ

    Change from baseline to Week 52 in SGRQ total score compared to placebo

    Time frame: Baseline to week 52

  5. Change in pre-bronchodilator FEV1

    Change in pre-bronchodilator FEV1 from baseline to week 52 compared to placebo.

    Time frame: Baseline to week 52

  6. Annual rate of acute COPD exacerbation

    Annualized rate of severe COPD exacerbations over the 52-week treatment period compared to placebo.

    Time frame: Baseline to week 52

  7. Change in post-bronchodilator FEV1

    Change in post-bronchodilator FEV1 from baseline to week 24 and 52 compared to placebo.

    Time frame: Baseline to week 24 and 52

  8. Change in EXACT

    Change from baseline to Week 52 in EXACT total score compared to placebo.

    Time frame: Baseline to week 52

  9. Adverse Events (AE) and Serious Adverse Events (SAE)

    The incidence and severity of AE and SAE, as well as abnormal laboratory examination index.

    Time frame: Baseline to 64 weeks

  10. Anti-drug antibodies (ADA)

    Incidence of ADA.

    Time frame: Baseline through week 52

  11. Immunoglobulin E (IgE)

    Changes in IgE levels in peripheral blood.

    Time frame: Baseline to 52 weeks

  12. Fractional exhaled nitric oxide (FeNO)

    Changes in FeNO.

    Time frame: Baseline to 52 weeks

07

Study locations

60 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Dec 2026, 24 months after the start.

Of 118 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's planned 24 months is above that.

Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2024
First posted
Nov 27, 2024
StartActual
Dec 31, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Sep 2027
Last update
Dec 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06707883
Responsible party
Sponsor
First posted
Nov 27, 2024
Start date
Dec 31, 2024
Primary completion
Dec 2026 (estimated)
Completion
Sep 2027 (estimated)
Last update
Dec 12, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TQC2731

Start the discussion